Par Pharmaceutical Companies Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Par Pharmaceutical Companies Inc.
Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Endo’s Par has partnered with Allergan to launch an authorized generic of Carafate sucralfate oral suspension in the US, competing directly with the first generic version recently launched by Amneal.
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.
- Other Names / Subsidiaries
- Anchen Pharmaceuticals, Inc.
- Edict Pharmaceuticals Private Limited
- JHP Pharmaceuticals, LLC
- Strativa Pharmaceuticals
- TPG Capital LP